新闻动态 News
查看更多 >>
-
2023-10-30近期,望石研发团队在计算生物学领域核心期刊《Computational and Structural Biotechnology Journal》上发表了题为《Using graph-based model to identify cell specific synthetic lethal effects》的研究论文,这是继团队在《Frontiers in Oncology》发表《Paralog-based synthetic lethality: rationales and applications》后,在合成致死(synthetic lethal)领域的又一学术成果。 合成致死(Synthetic Lethality)被认为是一种非常有潜力的精准肿瘤治疗和药物研发策略。通过鉴定细胞特异性的合成致死关系,可以有针对性地开发药物、制定精准治疗策略,甚至发现潜在的靶点。然而,目前的合成致死的预测方法存在一些问题,如数据量有限、对细胞背景差异考虑不足等,难以准确预测细胞特异性的合成致死关系。 为了解决上述问题,望石团队利用人工智能构建了一种新的预测模型。该模型具有以下特点:1)利用细胞特异的多组学数据,通过图编码学习基因之间的关系,提高对细胞特征的捕捉能力;2)利用自注意力机制,自动识别不同数据对预测任务的重要性;3)采...
-
2023-10-30近期,望石智慧团队在肿瘤权威期刊《Frontiers in Oncology》上发表了一篇关于合成致死研究的文章——《Paralog-based synthetic lethality: rationales and applications》。 合成致死(Synthetic Lethality)被认为是一种极具潜力的精准肿瘤治疗和药物研发策略。可以通过使用特定药物对携带特定突变的肿瘤中具有互补功能的基因进行靶向治疗,实现合成致死效应。这种方法能够导致目标基因功能的完全丧失,从而降低肿瘤细胞的活力,而对正常细胞无明显影响。旁系同源基因(Paralogs)是一组由基因复制而演化而来的相似基因,其功能相似性使针对它们的合成致死策略成为可能,因为一个基因的丧失并不会影响细胞的生存。此外,肿瘤细胞中旁系同源基因的纯合丧失比单一基因丧失更为频繁,使它们成为理想的合成致死靶标。目前已应用上市的PARP靶点也包含多个旁系同源基因,因此仍需要大量的机理研究来保证更多患者受益。 值得注意的是,尽管一对旁系同源基因会因为具有相似功能而产生直接针对肿瘤的合成致死关系,且高通量 CRISPR-Cas9 筛选发现...
-
2023-09-14高通量虚拟筛选(High-thoughput Virtual Screening,以下简称HTVS)在是药物设计领域发现苗头化合物的重要方法。如何提升HTVS的活性分子富集率是相关研究领域的核心问题。近期,望石研究团队在Nature Portfolio出版的Communications Chemistry上发表了成果Using macromolecular electron densities to improve the enrichment of active compounds in virtual screening,提出了ExptGMS(Experimental ED-based Grid Matching Score)方法,用于提升HTVS活性化合物的富集程度。 该方法也是继利用大分子实验电子密度驱动NCI研究与类药分子生成之后,望石研究团队的“大分子实验电子密度为数据基础的AIDD技术体系(框架体系见:JCIM封面文章|望石原创研究成果助力AIDD行业突破数据困境)”的又一新成果。 来自X射线晶体学的实验电子密度包含了配体、口袋、以及溶剂的动态信息。望石研究团队充分利用实验密度图的数据优势,构建了ExptGMS评分方法:首先通过实验密度构建打分网格,然后测量化合物的对接构象...
-
2023-07-11近期,北京望石智慧科技有限公司(以下简称“望石智慧”)披露了其与广州实验室联手开展了全新下一代口服新冠小分子抑制剂的开发项目。该项目仅用时12个月便完成了从立项至IND申报。在过往的研发环节中IND的成功申报通常耗时数以年计【1】,项目实现显著提速归功于双方项目组对于靶点蛋白及机制的深度理解、体系化的AIDD工作流程、极度高效的干湿实验互动。 AIGC模型在小分子化合物设计中可以显著提升前期命中率 整个过程中临床前候选化合物(PCC)确认仅用时4个月不到,“干实验”中的AIGC精准分子生成是保证项目快速推进的关键环节,仅用一至两轮的生成合成与测试便实现了分子设计、优化和提名的全部工作。该模型体系是望石智慧生成模型在小分子药物设计领域多年耕耘的重要产出之一。 以ChatGPT为代表的生成式人工智能,以在多种任务和领域中的卓越表现引起了广泛关注,并被寄予厚望。在小分子药物从头设计(de novo design)领域,如何精准的生成与靶点口袋结构契合的分子/分子骨架是公认的终极挑战目标。能够...
-
2023-06-29近期,望石研发团队在《Scientific Reports》上发表了题为《Deep learning model accurately classifies metastatic tumors from primary tumors based mutational signatures》的研究论文。 癌症转移是导致癌症患者死亡的主要原因,预测和阐明肿瘤转移的机制对于癌症治疗以及相关药物的研发至关重要。尽管已知体细胞突变与肿瘤发生和转移相关,但缺乏对突变过程的简明阐述和深入研究,难以据此判断个体癌症转移的风险。 在此次研究中,望石团队开发了一种深度学习模型MetaWise。该模型利用从TCGA和其他转移队列中获得的全外显子组测序数据计算得出的突变特征,可以有效区分转移性肿瘤和原发性肿瘤。此外,研究还发现非编码区域的突变特征对预测癌症转移风险也有重要影响。通过对模型预测结果进行解释性分析,望石团队确定了一些与不同肿瘤类型转移风险对应的相关突变特征及其潜在致病机制。 通过分析癌症患者的临床数据,此模型有望成为构建患者转移风险预测模型的基础。在临床中,可以为患者提供更加个性化的治疗方案,根据不同患者的转移风险水平...
-
2023-06-27“新冠疫情现在是一个既定和持续的卫生问题,不再构成国际关注的突发公共卫生事件... ...并不意味着新冠病毒不再是一个全球卫生威胁。” ——WHO总干事谭德塞 ”我们不能一劳永逸,因为病毒变化太快,产生了抗体后还是会感染... ...新冠病毒引起基础病加重,心脏病、神经系统病、肾脏病等 “ ——钟南山院士 为满足安全、低成本、适用人群广泛的常态化抗新冠的临床用药需求,望石智慧与广州实验室联手开展了二代口服新冠小分子抑制剂的开发项目,该项目仅用时12个月便完成了立项到IND申报,并获批。 近日,北京望石智慧科技有限公司(以下简称“望石智慧”)携手广州实验室合作开发的抗新冠小分子口服药物获得NMPA临床试验许可。该项目为国内首个进入临床阶段的二代3CL小分子口服抑制剂,自研发立项至IND申请仅用时12个月。 二代3CL抑制剂具备高吸收、代谢稳定等特征,未来临床应用可实现低剂量下单独给药。相比目前已上市的疗法,适用人群更为广泛,有望在长期用...
学术进展 Academic Progress
查看更多 >>
-
2022-04-27Abstract: The low-voltage activated T-type calcium channels regulate cellular excitability and oscillatory behavior of resting membrane potential which trigger many physiological events and have been implicated with many diseases. Here, we determine structures of the human T-type CaV3.3 channel, in the absence and presence of antihypertensive drug mibefradil, antispasmodic drug otilonium bromide and antipsychotic drug pimozide. CaV3.3 contains a long bended S6 helix from domain III, with a positive charged region protruding into the cytosol, which is critical for T-type CaV channel activation at low voltage. The drug-bound structures clearly illustrate how these structurally different compounds bind to the same central cavity inside the CaV3.3 channel, but are mediated by significantly distinct interactions between drugs and their surrounding residues. Pho...
-
2022-04-27Abstract: We report for the first time the use of experimental electron density (ED) in the Protein Data Bank for modeling of noncovalent interactions (NCIs) for protein–ligand complexes. Our methodology is based on reduced electron density gradient (RDG) theory describing intermolecular NCIs by ED and its first derivative. We established a database named Experimental NCI Database (ExptNCI; http://ncidatabase.stonewise.cn/#/nci) containing ED saddle points, indicating ∼200,000 NCIs from over 12,000 protein–ligand complexes. We also demonstrated the usage of the database in the case of depicting amide−π interactions in protein–ligand binding systems. In summary, the database provides details on experimentally observed NCIs for protein–ligand complexes and can support future studies including studies o...
-
2022-04-14Abstract: The increasing literature leads to formidable pressure for medical researchers. Most existing recommender approaches mainly depend on text-based information. How to extract and utilize the heterogeneous information, especially the graphic ones, to improve the recommender is worthy of further exploring. To this end, we establish a document-to-document recommender system for medical literature (D2D-MR). Specifically, we proposed HB-GED, the Half-branch GED algorithm, and the bipartite-graph-based algorithm for solving the molecule similarity and the paper similarity, respectively. Experimental results on real-world datasets demonstrate the effectiveness of the proposed recommender system. The Full Article Link: Doc-to-Doc Recommender for Medical Literature with Similarity of Molecule Graphs | IEEE Conference Publication | IEEE...
-
2022-01-07Abstract: Molecular scaffolds are widely used in drug design. Many methods and tools have been developed to utilize the information in scaffolds. Scaffold diversification is frequently used by medicinal chemists in tasks such as lead compound optimization, but tools for scaffold diversification are still lacking. Here, we propose AIScaffold , a web-based tool for scaffold diversification using the deep generative model. This tool can perform large-scale (up to 500,000 molecules) diversification in several minutes and recommend the top 500 (top 0.1%) molecules. Features such as site-specific diversification are also supported. This tool can facilitate the scaffold diversification process for medicinal chemists, thereby accelerating drug design. The Full Article Link: Journal of Chemical Information and Modeling | Vol 61, No 1 (acs.org) ...



